Physician profile
Stephen M Dechter
NPI 1568635365
$7,178.35
in general payments reported to CMS, 2019-2025
23 companies · $195 in 2025
The $195 reported for 2025 was less than what a typical Pain Medicine (Physical Medicine & Rehabilitation) provider received nationally (typical 2025 total: $400).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,810 · 2020: $1,404 · 2021: $104 · 2022: $508 · 2023: $456 · 2024: $702 · 2025: $195.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,346 · Travel and Lodging: $5.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,346.27 |
| Travel and Lodging | $5.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $4,896.93 | 2019-2024 | Senza |
| Boston Scientific Corporation | $756.64 | 2019-2025 | General - Pain Management |
| Stryker Corporation | $276.29 | 2024 | Aequalis Perform, Aequalis Ascend Flex, Aequalis Perform Reversed |
| Nalu Medical, INC. | $234.17 | 2022-2024 | Nalu Neurostimulation System |
| Zyla Life Sciences, INC. | $165.64 | 2019 | |
| Supernus Pharmaceuticals, INC. | $146.64 | 2019-2020 | |
| Medtronic USA, INC. | $118.11 | 2019 | |
| Relievant Medsystems, INC. | $85.14 | 2022 | |
| Daiichi Sankyo INC. | $67.60 | 2019 | |
| Mdd US Operations, LLC | $52.23 | 2019 | |
| Biotronik Nro, INC. | $51.52 | 2025 | Prospera |
| Pfizer INC. | $47.11 | 2019 | |
| Globus Medical, INC. | $40.33 | 2025 | Senza |
| Curonix LLC | $36.62 | 2023 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Lilly USA, LLC | $29.81 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fidia Pharma USA INC. | $29.71 | 2025 | Hymovis |
| Medtronic, INC. | $26.64 | 2021 | |
| Abbvie INC. | $23.50 | 2022 | |
| Collegium Pharmaceutical, INC. | $22.31 | 2019 | |
| Saluda Medical Americas, INC. | $22.04 | 2025 | Evoke |
| Abbott Laboratories | $20.73 | 2025 | Proclaim |
| Teva Pharmaceuticals USA, INC. | $15.70 | 2019 | |
| Novartis Pharmaceuticals Corporation | $12.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Dechter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.